PatentDe  


Dokumentenidentifikation EP1539795 13.12.2007
EP-Veröffentlichungsnummer 0001539795
Titel KRISTALLINES GAMMA-LACTON DER17BETA-HYDROXY-7ALPHA-(5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBONSÄURE
Anmelder Pharmacia & Upjohn Co. LLC, Kalamazoo, Mich., US
Erfinder PEARLMAN, Bruce Allen, Kalamazoo, MI 49008, US;
ANTOSZ, Frederick J., Kalamazoo, MI 49009, US
Vertreter derzeit kein Vertreter bestellt
DE-Aktenzeichen 60317214
Vertragsstaaten AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
Sprache des Dokument EN
EP-Anmeldetag 19.09.2003
EP-Aktenzeichen 037744885
WO-Anmeldetag 19.09.2003
PCT-Aktenzeichen PCT/US03/29923
WO-Veröffentlichungsnummer 2004037844
WO-Veröffentlichungsdatum 06.05.2004
EP-Offenlegungsdatum 15.06.2005
EP date of grant 31.10.2007
Veröffentlichungstag im Patentblatt 13.12.2007
IPC-Hauptklasse C07J 21/00(2006.01)A, F, I, 20051017, B, H, EP

Beschreibung[en]
BACKGROUND OF THE INVENTION 1. Field of the Invention

The present invention is a novel crystal form of 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone.

2. Description of the Related Art

There is no reliable method to predict the existence of a crystal form of a pharmaceutical. Further, if a material is crystalline there is no reliable method to predict its physical properties. Therefore, patents to novel crystal forms are well known. For example, US Patent 3,565,924 discloses and claims 25-hydroxycocalciferol (25-HCC) which is a non-crysalline solid. Later a novel crystal form, 25-HCC hemihydrate was patented, see US Patent 3,833,622 . US Patent 4,521,431 discloses crystal forms 1 and 2 of ranitidine hydrochloride. US Patent 4,504,657 claims "crystalline 7-[D-alpha-(p-hydroxyphenyl)acetamido]-3-methyl-3-cephem-4-carboxylic acid monohydrate. US Patent 6,452,007 B1 claims the "S" and "T" crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]4-[3-(1-methylethylamino)-2-pyridinyl]piperazine. US Patent 6,444,813 B2 claims a novel crystal form of a known antibacterial agent, linezolid.

International Publications WO01/41535 and WO01/42272 disclose crystal forms of pharmaceutical agent eplerenone.

SUMMARY OF INVENTION

Disclosed is 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone a compound of the formula in crystalline form having a powder X-ray diffraction spectrum of: Two-Theta Angle (°) with a range of From To 6.46 6.59 10.46 10.70 11.48 11.70 12.55 12.79 14.19 14.36 15.06 15.30 16.10 16.65 16.55 16.74 17.79 18.01 18.25 18.46 19.46 19.70 20.06 20.30 20.86 21.25 21.60 21.80 23.14 23.35 24.74 24.95 25.15 25.96 25.85 26.05 27.35 27.55 28.26 28.90 28.75 28.85 29.91 30.14 30.90 31.10 31.86 32.05 32.59 32.79 33.14 33.89 33.63 34.00 34.27 34.49 35.52 35.75 36.06 36.30 37.02 37.21 37.74 37.91 38.42 38.64 39.35 39.39
to a reasonable degree of scientific certainty, where

Two-Theta Angle is measured in degrees.

Also disclosed is 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone in crystalline form having a powder X-ray diffraction spectrum of: Two-Theta Angle (°) and Relative Intensity (%) with a ranges of: Two-Theta Angle (°) Relative Intensity (%) From To From To 6.46 6.59 1.0 1.6 10.46 10.70 10.7 58.3 11.48 11.70 11.7 20.8 12.55 12.79 2.2 4.2 14.19 14.36 14.4 100.0 15.06 15.30 15.3 29.5 16.10 16.65 7.2 50.3 16.55 16.74 16.7 66.4 17.79 18.01 18.0 100.0 18.25 18.46 18.5 34.5 19.46 19.70 6.1 12.6 20.06 20.30 19.5 28.1 20.86 21.25 16.1 36.3 21.60 21.80 10.8 20.0 23.14 23.35 23.3 48.0 24.74 24.95 11.5 19.0 25.15 25.96 4.4 30.3 25.85 26.05 12.1 31.2 27.35 27.55 9.5 22.7 28.26 28.90 2.1 6.2 28.75 28.85 6.6 11.1 29.91 30.14 1.9 3.5 30.90 31.10 5.6 10.4 31.86 32.05 1.2 3.7 32.59 32.79 0.9 2.3 33.14 33.89 1.6 4.5 33.63 34.00 1.1 4.9 34.27 34.49 1.4 2.2 35.52 35.75 1.3 3.9 36.06 36.30 7.9 27.0 37.02 37.21 3.9 6.2 37.74 37.91 1.0 2.2 38.42 38.64 1.2 2.9 39.35 39.39 1.6 1.8
to a reasonable degree of scientific certainty, where

Two-Theta Angle is measured in degrees and

Relative Intensity is the intensity percentage of each peak relative to the strongest peak.

Further disclosed is 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone in crystalline form having a powder X-ray diffraction spectrum of Two-Theta Angle (°), d-spacing ( ) and Relative Intensity (%) with ranges of: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) From To From To From To 6.46 6.59 13.39 13.66 1.0 1.6 10.46 10.70 8.26 8.45 10.7 58.3 11.48 11.70 7.56 7.70 11.7 20.8 12.55 12.79 6.92 7.05 2.2 4.2 14.19 14.36 6.16 6.24 14.4 100.0 15.06 15.30 5.79 5.88 15.3 29.5 16.10 16.65 5.32 5.50 7.2 50.3 16.55 16.74 5.29 5.35 16.7 66.4 17.79 18.01 4.92 4.98 18.0 100.0 18.25 18.46 4.80 4.86 18.5 34.5 19.46 19.70 4.50 4.56 6.1 12.6 20.06 20.30 4.37 4.42 19.5 28.1 20.86 21.25 4.18 4.26 16.1 36.3 21.60 21.80 4.07 4.11 10.8 20.0 23.14 23.35 3.81 3.84 23.3 48.0 24.74 24.95 3.57 3.60 11.5 19.0 25.15 25.96 3.43 3.54 4.4 30.3 25.85 26.05 3.42 3.44 12.1 31.2 27.35 27.55 3.24 3.26 9.5 22.7 28.26 28.90 3.09 3.16 2.1 6.2 28.75 28.85 3.09 3.10 6.6 11.1 29.91 30.14 2.96 2.98 1.9 3.5 30.90 31.10 2.87 2.89 5.6 10.4 31.86 32.05 2.79 2.81 1.2 3.7 32.59 32.79 2.73 2.75 0.9 2.3 33.14 33.89 2.64 2.70 1.6 4.5 33.63 34.00 2.63 2.66 1.1 4.9 34.27 34.49 2.60 2.61 1.4 2.2 35.52 35.75 2.51 2.53 1.3 3.9 36.06 36.30 2.47 2.49 7.9 27.0 37.02 37.21 2.41 2.43 3.9 6.2 37.74 37.91 2.37 2.38 1.0 2.2 38.42 38.64 2.33 2.34 1.2 2.9 39.35 39.39 2.29 2.29 1.6 1.8
to a reasonable degree of scientific certainty, where

Two-Theta Angle is measured in degrees,

d-Spacing is measured in angstroms, and

Relative Intensity is the intensity percentage of each peak relative to the strongest peak.

DETAILED DESCRIPTION OF THE INVENTION

Eplerenone is 9&agr;,11&agr;-epoxy-17&bgr;-hydroxypregn-4-en-3-one-7&agr;,21-dicarboxylic acid, &ggr;-lactone, methyl ester and as such contains a 7&agr;-carbomethoxy substituent. It is useful as a pharmaceutical agent for the treatment of hypertension and congestive heart failure. A major difficulty in the production of eplerenone is introduction of the 7&agr;-carbomethoxy substituent. The intermediates of the present invention are involved in improved processes for the preparation of eplerenone.

The preferred method of purification of 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone is by crystallization. The process for purifying 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone comprises crystallizing 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone, which contains greater than 5% of the 7&bgr;-isomer from a solvent selected from the group consisting of ethyl acetate, n-propyl acetate and butyl acetate. It is preferred to obtain the 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone in greater than 99.8% isomeric purity and it is preferred that the crystallization solvent is n-propyl acetate. Crystallization co-solvents may be used. The above purification results in crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone. However, crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone can also be readily obtained from other solvents, including methylene chloride, methanol, acetonitrile, acetone, cyclohexane and iso-octane as well as solvent mixtures of these solvents or a mixture of acetonitrile with water. Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone can be readily obtained by methods well known to those skilled in the art for crystallization. For example, 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone desired to be obtained in crystalline form is dissolved in a minimal amount of a suitable solvent, the mixture is heated until all 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone is in solution and then the mixture is cooled until crystals result. Alternatively, once 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone is in solution in a suitable solvent such as ethyl acetate, the volume of the solvent can be reduced by distillation, or by passing a stream of a dry inert gas such as nitrogen over the mixture to concentrate 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone. Further, anti-solvents, such as cyclohexane or iso-octane, can be added to the warm mixture to help reduce the solubility of 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone in the solvent and promote its crystallization as is known to those skilled in the art. The preferred solvents for crystallization are those used for purification.

It has been determined by powder X-ray diffraction (PXRD) that the crystals of 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone regardless of which process of the invention was used to make it and regardless of what solvent(s) it is crystallized from, that only one crystal form is produced. EXAMPLEs 7-21 are PXRD analysis of different samples of crystalline 17&bgr;-hydroxy-7&agr; (5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone obtained by various process and crystallized from various solvent systems. The results are substantially identical. The differences are due to the identity and amount of a particular impurity that may be present as well as residual solvent as is known to those skilled in the art. It is known to those skilled in the art that even if the same sample is subjected to PXRD on more than one occasion, that the results will not be identical. That is know as experimental error and understood by those skilled in the art. It is the overall analysis that determines whether or not two crystal forms are the same or different.

In determining the PXRD of a crystal, the particular instrument used as well as the power of the instrument will affect the results. In determining whether two samples have the same or different crystal form, a scientist will compare the location of peaks or bands and look to see if there are any new bands in either sample not present in the other. In addition, the relative intensity of the peaks is very important.

DEFINITIONS AND CONVENTIONS

The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.

DEFINITIONS

All temperatures are in degrees Celsius.

TLC refers to thin-layer chromatography.

LC refers to liquid chromatography.

ESTDLC refers to external standard liquid chromatography.

THF refers to tetrahydrofuran.

DMAP refers to p-dimethylaminopyridine.

DDQ refers to 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

DBU refers to 1,8-diazabicyclo[5.4.0]undec-7-ene.

DBN refers to 1,5-diazabicyclo[4.3.0]non-5-ene.

DABCO refers 1,4-diazabicyclo[2.2.2]octane.

Chromatography (column and flash chromatography) refers to purification/separation of compounds expressed as (support, eluent). It is understood that the appropriate fractions are pooled and concentrated to give the desired compound(s).

Carboxylic acid (VI) refers to and includes the pharmaceutically acceptable salts thereof.

CMR refers to C-13 magnetic resonance spectroscopy, chemical shifts are reported in ppm (&dgr;) downfield from TMS.

NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (d) downfield from TMS.

In the present invention the terms conversion/transformation or convert/transform are used interchangeable and mean the same thing, the reaction of one compound to form a different compound by the process described.

TMS refers to trimethylsilyl.

Oxone refers to KHSO5.

-&phgr; refers to phenyl (C6H5).

MS refers to mass spectrometry expressed as m/e, m/z or mass/charge unit. [M + H]+ refers to the positive ion of a parent plus a hydrogen atom. EI refers to electron impact. CI refers to chemical ionization. FAB refers to fast atom bombardment.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

When solvent pairs are used, the ratios of solvents used are volume/volume (v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).

&Dgr;9-Canrenone refers to 17&bgr;-hydroxypregna-4,6,9-trien-3-one-21-carboxylic acid, &ggr;-lactone.

Eplerenone refers to 9&agr;,11&agr;-epoxy-17&bgr;-hydroxypregn-4-en-3-one-7&agr;,21-dicarboxylic acid, &ggr;-lactone, methyl ester.

Neopentylglycol refers to HO-CH2-C(CH3)2-CH2-OH.

Iodosobenzene refers to ϕI=O.

Iodobenzenebistrifluoroacetate refers to ϕI(O-CO-CF3)2.

Iodobenzenediacetate refers to ϕI(O-CO-CH3)2.

Tritylfluoroborate is also known as triphenylcarbenium fluoroborate and refers to ϕ3C+BF4 -.

acac refers to acetylacetonate.

dppb refers to diphenylphosphino butane.

Tf refers to trifluoromethanesulfonate.

Dimethylsulfide refers to CH3SCH3.

Ishikawa reagent refers to N-(1,1,2,2,3,3,3)hexafluoropropyldiethylamine.

A "deoxygenating agent" is a reagent that removes one oxygen atom from a molecule. The "hydroperoxy-deoxygenating agent" is thus a particular type of deoxygenating agent.

PXRD refers to powder X-ray diffraction.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

EXAMPLE 1 17&bgr;-Hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

&Dgr;9-canrenone (I, 90.0 g, 0.2659 moles) is mixed with nitromethane (730-735 ml). Then 2-methylfuran (49.5 ml, 45.04 g, 0.5487 moles, 2.06 equivalents) is added. The resulting mixture is cooled to -20° then treated with absolute ethanol (15.8 ml, 12.55 g, 0.2723 moles, 1.02 equivalents) followed by boron trifluoride etherate, (d = 1.120; 37.2 ml, 41.66 g, 0.2936 moles, 1.10 equivalents). The mixture is recooled to -18.4° and stirred for 17 hrs., at which time the reaction was complete by LC. The reaction mixture is quenched with ammonia (15% aqueous, 225 ml). The mixture is warmed to above 0°, water (200 ml) is added, the organic phase is separated, and the aqueous phase is extracted with methylene chloride (2 x 200 ml). The organic extracts are dried over magnesium sulfate (100 g) then filtered through magnesol (100 g cartridge grade), washing the cake with methylene chloride (5 x 200 ml). The eluate is then concentrated under reduced pressure to a foam, slurried with ethyl acetate (200 ml) and reconcentrated, then dissolved in ethyl acetate (950 ml) at 50° to 60°. The mixture is concentrated to about 500 ml volume, then diluted with cyclohexane (250 ml). The product begins to crystallize slowly. The slurry is reconcentrated to about 500 ml volume, cooled to 20-25°, further concentrated to about 400 ml volume, then cooled to 0°. After overnight at 0°, the slurry is filtered and the cake washed with cyclohexane followed by heptane and dried in a vacuum oven at 50° to give the title compound, TLC = 0.37 (ethyl acetate/cyclohexane, 66/34), CMR(CDCl3) 13.38, 14.12, 23.18, 26.83, 29.14, 31.26, 32.93, 33.93, 34.18, 35.39, 37.57, 38.52, 40.78, 41.90, 42.39, 44.08, 95.19,105.89, 107.12, 119.73, 126.24, 149.99, 152.74, 167.45, 76.53 and 198.56; NMR(CDCl3) 0.95, 1.43, 1.4-2.6, 2.16, 2.93, 3.30, 5.68 and 5.74 &dgr;.

The filtrate is concentrated to a foam which is dissolved in ethyl acetate (40 ml), concentrated to about 20 ml, seeded, diluted with cyclohexane (20 ml), concentrated to about 30 ml, cooled to 0° over the weekend, then filtered, washed with ethyl acetate/cyclohexane (1/2) and dried to give additional title compound.

EXAMPLE 2 11&agr;,17&bgr;-Dihydroxy-7&agr;-(5'-methyl-2'-furyl)-pregn-4-en-3-one-21-carboxylic acid, &ggr;-lactone (II)

A mixture of 11&agr;-hydroxycanrenone (I, 30.00 g, 84.1586 mmoles) in nitromethane (240 ml) and methylene chloride (60 ml) is cooled to 20° then treated with 2-methylfuran (15.6 ml, 14.20 g, 0.1729 moles, 2.05 equivalents) followed by ethanol (5.1 ml, 4.03 g, 87.454 mmoles, 1.04 equivalents) followed by boron trifluoride diethyl etherate (BF3·OEt2, 12.0 ml,13.44 g, 94.695 mmoles, 1.13 equivalents). The reaction mixture is stirred at -17° for 20 hrs., then quenched with ammonia (15% aqueous, 60 ml), extracted with methylene chloride (120 ml), dried over sodium sulfate (40 g) and concentrated. The concentrate is dissolved in methylene chloride/ethyl acetate (1/1, 300 ml) concentrated to a volume of 75 ml, diluted with 150 ml cyclohexane, concentrated to a volume of 200 ml, and filtered to give the title compound, CMR (75 MHz, CDCl3) 199.59, 176.67, 170.11, 152.92,150.28,126.20, 108.67, 105.90, 95.18, 68.55, 52.05, 45.84, 45.58, 43.08, 39.73, 38.62, 38.42, 37.47, 36.54, 35.26, 34.17, 30.91, 29.05, 22.62, 18.40, 15.58 and 13.44 &dgr;; NMR (300 MHz, CDCl3) 1.01, 1.1-3.2, 1.41, 2.20, 4.12, 5.73, 5.83 and 5.93 &dgr;.

The filtrate is concentrated. The concentrate is taken up in ethyl acetate (30 ml warm), cooled to 10°, and filtered to give a second crop of crystal of the title compound.

EXAMPLE 3 17&bgr;-Hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

A mixture of 11&agr;,17&bgr;-dihydroxy-7&agr;-(5'-methyl-2'-furyl)-pregn-4-en-3-one-21-carboxylic acid, &ggr;-lactone (II, EXAMPLE 12,438.3 mg, 0.9994 mmoles) in THF (7.3 ml) is cooled to -50°, then treated all at once with solid phosphorous pentachloride, (PCI5, 287.5 mg,1.381 mmoles, 1.38 equivalents). After stirring for 42 min., analysis by LC indicates that conversion to the title compound is complete. After another 21 min., the mixture is quenched with water (22 ml) and warmed to 20-25°. After 20 min., the mixture is extracted with methylene chloride (2 x 15 ml), dried over magnesium sulfate, and concentrated to give the title compound, identified by LC retention time comparison with a sample from EXAMPLE 1.

EXAMPLE 4 17&bgr;-Hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 1, using the same reactants and making non-critical variations, the title compound is obtained, CMR (100 MHz, CDCl3) 198.56, 176.53, 167.45, 152.74, 149.99, 142.84,126.24,119.73, 107.12, 105.89, 95.19, 44.08, 42.39, 41.90, 40.78, 38.52, 37.57, 35.39, 34.18, 33.93, 32.93, 31.26, 29.14, 26.83, 23.18, 14.12 and 13.38 &dgr;; NMR (400 MHz, CDCl3) 0.95, 1.43, 1.4-2.6, 2.16, 2.93 and 5.7 &dgr;.

EXAMPLE 5 17&bgr;-Hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

A mixture of &Dgr;9-canrenone (I, 105 g, 0.31024 moles) in acetonitrile (450 ml) is treated with ethanol (21.0 g, 0.4558 moles, 1.47 equivalents), isopropanol (1.5 ml, 1.177 g, 19.592 mmoles, 0.063 equivalents), and 2-methylfuran (48.5 g, 0.5907 moles, 1.90 equivalents), then cooled to -18° and treated with boron trifluoride diethyl etherate (63.0 g, 0.4439 moles, 1.43 equivalents) over 4 hours. After stirring at -18° for 24 hrs., the mixture is quenched with triethylamine (38.0 g, 0.3755 moles, 1.21 equivalents) and concentrated to a thick slurry, which is diluted with water (350 ml), extracted with methylene chloride (400 ml), washed with water (350 ml), then concentrated, n-propyl acetate added, and further concentrated to give a slurry, which is cooled to 0°, filtered, and the cake washed with n-propyl acetatelmethyl-t-butyl ether (1/1) followed by methyl-t-butyl ether to give the title compound, identified by LC retention time comparison with a sample from EXAMPLE 1.

EXAMPLE 6 17&bgr;-Hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Ishikawa reagent (2.4 mK, 13.7 mmol) is added to a mixture of 11&agr;,17&bgr;-dihydroxy 7&agr;-(5'-methyl-2'-furyl)-prego-4-en-3-one-21-carboxylic acid, &ggr;-lactone (II, EXAMPLE 2,5 g, 11.4 mmol) in acetonitrile (25 mL). The mixture is heated to 60° and is determined complete in 1 hr by HPLC. The resulting mixture is cooled to 22° and quenched with saturated aqueous sodium bicarbonate (15 mL). The organic solvent is removed under reduced pressure and replaced with methylene chloride (50 mL). The organic phase is separated, washed with water (30 mL) and concentrated to a volume of 20 mL. Water (30 mL) is added and the mixture is concentrated to a volume of 20 mL. This water distillation is repeated twice to remove the N,N-diethyl-2,3,3,3-tetrafluoropriopionamide by-product. Then, methylene chloride (30 mL) is added to the resulting slurry to dissolve all solids. The organic layer is separated and the solvent is exchanged to n-propyl acetate to a final volume of 17-18 mL. The resulting slurry is cooled to 20° for 12 hours. The product was collected by filtration and dried under ambient nitrogen to give the title compound, mp = 198-203°; NMR (400 MHz, CDCl3) 5.737, 5.690, 3.300, 2.904, 2.164, 1.431, 0.952 and 2.569-1.358 &dgr;; CMR (100 MHz, CDCl3) 198.5, 176.5, 167.4, 152.7,150.0, 142.8, 126.2, 119.7, 107.1, 105.9, 95.2, 44.1, 42.4, 41.9, 38.5, 37.6, 35.4, 33.9, 32.9, 31.3, 29.1, 26.8, 23.2,14.1 and 13.4 &dgr;; MS calculated for C27H33O4=421.238 (M + H+), found = 421.2 m/z.

EXAMPLE 7 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

A sample of 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) produced by the process of one of EXAMPLEs 1 or 3-6 or following the general procedure of these EXAMPLEs and making non-critical variations, is obtained in crystalline form and tested by powder X-ray diffraction (PXRD) as follows. 17&bgr;-Hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is ground for 30 seconds using a mortar and pestle. The ground sample is placed on zero-background sample holders containing a thin layer of Vaseline. The sample is examined by PXRD using the Rigaku Miniflex X-ray diffractometer. The diffraction pattern is collected with the sample spinning.

Experimental Conditions for Powder X-Ray Diffraction (XRD): A Rigaku Miniflex+ X-ray diffractometer was used for the acquisition of the powder XRD patterns. The instrument operates using the Cu K&agr;1 emission with a nickel filter at 1.50451. The major instrumental parameters are set or fixed at: X-ray: Cu /30 kV (fixed) /15 mA (fixed) Divergence Slit: Variable Scattering Slit: 4.2° (fixed) Receiving Slit: 0.3 mm (fixed) Scan Mode: FT Preset Time: 2.0 sec. Scan Width: 0.050° Scan Axis: 2Theta/Theta Scan Range: 3.000° to 40.000°
The results of the PXRD are as follows: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.503 13.5812 1.1 10.589 8.3479 58.3 11.557 7.6505 18.2 12.686 6.9721 4.0 14.248 6.2111 100.0 15.144 5.8455 28.3 16.608 5.3334 50.6 17.851 4.9647 84.5 18.353 4.8300 28.2 19.537 4.5399 8.3 20.148 4.4037 22.6 21.147 4.1977 28.0 21.695 4.0930 18.6 23.199 3.8309 35.1 24.757 3.5933 13.5 25.241 3.5255 6.0 25.905 3.4365 25.7 27.400 3.2523 18.1 28.262 3.1551 2.5 28.750 3.1026 8.4 29.955 2.9805 2.9 30.959 2.8861 8.2 31.950 2.7988 3.6 32.685 2.7375 2.3 33.207 2.6957 3.2 33.888 2.6431 4.0 34.356 2.6081 1.7 35.607 2.5193 2.7 36.144 2.4831 25.6 37.061 2.4237 4.5 37.797 2.3782 1.4 38.496 2.3366 2.4
where

  • Two-Theta Angle is measured in degrees;
  • d-Spacing is measured in angstroms; and
  • Relative Intensity is the intensity percentage of each peak relative to the strongest peak at 14.248 degrees.

EXAMPLE 8 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.506 13.5742 1.1 10.603 8.3366 49 11.600 7.6220 17.7 12.699 6.9648 2.4 14.297 6.1900 100 15.159 5.8398 18.8 16.206 5.4648 7.2 16.650 5.3202 39.6 17.900 4.9512 59.4 18.397 4.8186 27 19.593 4.5270 8.5 20.155 4.4022 27.5 21.194 4.1886 22.4 21.702 4.0916 15.7 23.247 3.8231 24.5 24.805 3.5865 13.1 25.256 3.5234 6.2 25.948 3.4310 29.2 27.452 3.2464 14.8 28.353 3.1452 3 28.800 3.0974 7.3 29.952 2.9808 2.2 31.003 2.8821 7.2 31.988 2.7956 3.3 32.666 2.7391 1.3 33.245 2.6926 3.4 33.902 2.6420 2 34.392 2.6055 1.4 35.651 2.5163 1.9 36.192 2.4799 14.9 37.105 2.4209 4.4 37.817 2.3770 1.6 38.547 2.3336 2.4 39.394 2.2854 1.6

EXAMPLE 9 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregria-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.536 13.5120 1.2 10.505 8.4141 43.6 11.548 7.6564 15.7 12.613 7.0121 3.6 14.251 6.2099 100 15.142 5.8463 29.2 16.598 5.3368 31.6 17.848 4.9655 59.3 18.349 4.8310 34.5 19.543 4.5386 11.7 20.140 4.4054 24.3 21.002 4.2264 29.1 21.653 4.1008 15 23.197 3.8312 48 24.754 3.5936 14 25.945 3.4314 25 27.403 3.2520 21.4 28.749 3.1027 11.1 29.991 2.9770 2.2 30.953 2.8867 8.1 31.857 2.8067 3 32.683 2.7376 1.4 33.667 2.6599 3.3 36.106 2.4856 13.5 37.054 2.4242 5.5 37.795 2.3783 2.2 38.460 2.3387 2.7

EXAMPLE 10 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-ftuyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy 7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.508 13.5698 1.4 10.590 8.3470 51.6 11.549 7.6557 16.7 12.614 7.0118 2.5 14.247 6.2116 100 15.147 5.8443 25.2 16.156 5.4815 8.5 16.637 5.3241 42.4 17.854 4.9638 66.6 18.345 4.8320 27.2 19.547 4.5376 9.5 20.143 4.4048 26.2 21.051 4.2167 28.1 21.691 4.0937 17.4 23.240 3.8243 34.5 24.797 3.5875 13.2 25.207 3.5301 7.1 25.903 3.4368 25.8 27.404 3.2519 16.1 28.261 3.1552 2.1 28.752 3.1024 7.4 29.994 2.9767 2.3 30.955 2.8865 9.7 31.938 2.7999 2.9 32.586 2.7456 2 33.196 2.6965 3.2 33.711 2.6565 2.3 34.315 2.6111 1.4 35.642 2.5169 3.2 36.147 2.4829 16.2 37.092 2.4218 4.1 37.798 2.3781 2.1 38.469 2.3382 2.1

EXAMPLE 11 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (ll) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 10.596 8.3424 29.9 11.597 7.6245 16.6 12.658 6.9877 2.6 14.296 6.1904 100 15.192 5.8272 23.4 16.652 5.3193 30.3 17.899 4.9514 46.1 18.401 4.8176 29.1 19.557 4.5352 8.5 20.158 4.4015 24.5 21.000 4.2269 21.8 21.706 4.0909 14.4 23.246 3.8232 32 24.846 3.5805 13.6 25.953 3.4303 17.7 27.447 3.2469 15 28.798 3.0976 7.5 30.002 2.9760 2.7 31.003 2.8821 7.5 31.955 2.7984 1.2 32.697 2.7366 1.5 33.247 2.6925 4.2 33.708 2.6567 1.7 34.372 2.6069 1.6 35.645 2.5167 1.9 36.154 2.4824 11.1 37.145 2.4184 4.4 37.843 2.3754 1.3 38.537 2.3342 2.5

EXAMPLE 12 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 10.647 8.3025 40.1 11.602 7.6207 16.1 12.747 6.9388 3.3 14.300 6.1887 100 15.194 5.8263 25.7 16.692 5.3068 40.3 17.945 4.9389 68.4 18.401 4.8176 31.3 19.591 4.5275 8.5 20.154 4.4023 28.1 21.003 4.2262 26.5 21.707 4.0908 15.6 23.247 3.8231 34.4 24.847 3.5804 19 25.956 3.4300 30.3 27.451 3.2464 18.5 28.845 3.0926 9.8 29.958 2.9802 3.5 31.044 2.8784 9.7 32.039 2.7912 1.6 32.716 2.7350 2 33.256 2.6918 4.5 33.713 2.6564 2.8 34.330 2.6100 2.2 35.652 2.5162 3.2 36.196 2.4796 17 37.146 2.4184 5.9 37.804 2.3778 2.2 38.544 2.3338 2.7

EXAMPLE 13 Crystalline 17&bgr;-hydroxy-7&agr;-(5-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.594 13.3929 1 10.604 8.3359 42.2 11.602 7.6212 16.6 12.699 6.9652 2.8 14.305 6.1866 100 15.200 5.8242 29.4 16.654 5.3188 50.3 17.943 4.9395 74.3 18.442 4.8069 27 19.607 4.5239 10 20.200 4.3925 23.9 21.051 4.2166 28.2 21.746 4.0834 16.8 23.291 3.8161 32.9 24.851 3.5798 13.5 25.299 3.5175 8.1 25.994 3.4250 27.2 27.456 3.2458 18.3 28.352 3.1453 3.1 28.845 3.0926 8 30.053 2.9710 2.9 31.005 2.8819 7.5 31.949 2.7989 2.3 33.254 2.6920 3.5 33.949 2.6384 2.6 34.400 2.6049 1.9 35.653 2.5162 3.2 36.196 2.4796 16.2 37.190 2.4156 5.1 37.840 2.3756 1.9 38.554 2.3332 2.9

EXAMPLE 14 Crystalline 17&bgr;-hydroxy 7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 10.699 8.2622 53.4 11.702 7.5562 11.8 12.790 6.9156 2.2 14.356 6.1644 73.4 15.298 5.7872 21.2 16.743 5.2908 66.4 18.005 4.9225 100 18.456 4.8034 23.1 19.698 4.5031 6.6 20.297 4.3716 23 21.252 4.1772 29 21.800 4.0735 10.8 23.348 3.8068 29.8 24.949 3.5661 12 25.346 3.5111 4.4 26.003 3.4238 28.7 27.547 3.2353 17.1 28.494 3.1300 4.4 28.854 3.0917 6.6 30.140 2.9626 1.9 31.103 2.8731 7.1 32.054 2.7900 3.7 33.316 2.6871 1.6 33.999 2.6347 4.9 35.751 2.5095 2.5 36.297 2.4730 27 37.206 2.4146 3.9 37.908 2.3715 1.5 38.643 2.3281 2.3

EXAMPLE 15 Crystalline 17&bgr; hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II))

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.557 13.4698 1.2 10.641 8.3067 49.6 11.608 7.6171 12.6 12.708 6.9603 2.5 14.340 6.1713 100 15.205 5.8221 27.9 16.698 5.3048 54.7 17.947 4.9383 84 18.446 4.8060 29.1 19.606 4.5242 12.6 20.202 4.3921 25.9 21.053 4.2162 32.2 21.752 4.0824 19.1 23.295 3.8153 43.7 24.855 3.5793 14.8 25.300 3.5173 7 25.998 3.4245 31.2 27.498 3.2410 21.1 28.358 3.1447 3.3 28.846 3.0925 9.9 30.084 2.9680 2.6 31.053 2.8776 9.9 31.962 2.7978 2.7 32.779 2.7299 1.5 33.288 2.6893 3.3 33.762 2.6527 3.5 34.384 2.6060 1.8 35.701 2.5129 3.9 36.200 2.4794 18.6 37.155 2.4178 5 37.896 2.3722 1.8 38.557 2.3330 2.8

EXAMPLE 16 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (ll)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5' -methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.534 13.5158 1.4 10.545 8.3820 53 11.547 7.6569 13 12.644 6.9952 2.6 14.248 6.2112 100 15.146 5.8447 27.4 16.597 5.3369 55.8 17.851 4.9648 84.3 18.349 4.8312 28.9 19.542 4.5388 12.4 20.144 4.4045 23.5 21.001 4.2267 36.3 21.692 4.0936 20 23.200 3.8308 45.9 24.797 3.5876 12.9 25.239 3.5256 6.1 25.902 3.4369 31.2 27.403 3.2520 22.7 28.259 3.1554 3.8 28.751 3.1025 9.9 29.990 2.9771 2.4 30.995 2.8828 10.4 31.863 2.8063 3.2 32.683 2.7377 1.7 33.889 2.6430 3.7 35.642 2.5169 3 36.143 2.4831 19.1 37.098 2.4214 5 37.801 2.3780 1.9 38.503 2.3362 2.4

EXAMPLE 17 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(II)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;(5'-methyl-2'-furyl)-pregna-4,9(11)dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.464 13.6629 1.1 10.457 8.4529 28.8 11.482 7.7003 20.8 12.546 7.0495 4.2 14.185 6.2387 100.0 15.056 5.8797 27.6 16.099 5.5007 7.2 16.545 5.3536 25.9 17.792 4.9810 37.9 18.253 4.8563 26.8 19.455 4.5590 8.7 20.056 4.4237 22.6 20.858 4.2552 17.2 21.604 4.1100 12.8 23.139 3.8407 36.5 24.741 3.5955 11.5 25.152 3.5377 7.4 25.848 3.4440 12.7 27.347 3.2585 13.6 28.700 3.1079 6.2 29.910 2.9849 2.3 30.898 2.8917 5.6 32.599 2.7445 1.5 33.142 2.7008 3.5 33.633 2.6625 1.4 34.265 2.6148 1.5 35.520 2.5252 1.3 36.055 2.4890 8.1 37.016 2.4266 4.4 37.735 2.3820 1.0 38.415 2.3413 2.4 39.349 2.2879 1.8

EXAMPLE 18 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-progna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with spin with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 10.652 8.2987 21.1 11.647 7.5915 18.4 12.751 6.9370 2.4 14.350 6.1673 100.0 15.252 5.8044 22.5 16.303 5.4325 8.5 16.707 5.3020 19.7 17.996 4.9252 29.0 18.455 4.8037 24.7 19.679 4.5076 6.1 20.247 4.3823 21.0 21.058 4.2154 16.1 21.759 4.0812 12.6 23.343 3.8076 27.8 24.899 3.5731 12.2 25.346 3.5111 6.1 26.050 3.4177 12.1 27.542 3.2358 9.5 28.899 3.0870 5.7 30.099 2.9666 2.3 31.100 2.8733 5.6 32.042 2.7909 1.3 32.790 2.7290 2.2 33.346 2.6848 4.5 33.801 2.6496 1.1 34.489 2.5983 1.4 35.708 2.5124 1.8 36.244 2.4765 7.9 37.208 2.4145 - 5.0 37.912 2.3712 1.5 38.599 2.3306 1.2

EXAMPLE 19 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-laetone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.575 13.4329 1.1 10.552 8.3766 29.8 11.551 7.6546 15.3 12.608 7.0148 3.0 14.256 6.2077 100.0 15.150 5.8432 28.5 16.606 5.3342 29.7 17.856 4.9633 49.9 18.353 4.8301 20.9 19.587 4.5284 7.8 20.187 4.3952 19.5 20.955 4.2357 17.2 21.696 4.0928 15.4 23.242 3.8239 41.8 24.800 3.5871 13.5 25.237 3.5260 5.2 25.948 3.4310 17.2 27.449 3.2467 16.2 28.794 3.0979 8.1 29.956 2.9804 2.5 30.997 2.8826 5.9 32.661 2.7395 0.9 33.210 2.6955 3.2 33.801 2.6497 2.6 34.398 2.6050 1.6 35.600 2.5197 1.7 36.145 2.4830 11.9 37.107 2.4208 4.0 37.801 2.3780 1.4 38.531 2.3346 2.1

EXAMPLE 20 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.575 13.4329 1.1 10.552 8.3766 29.8 11.551 7.6546 15.3 12.608 7.0148 3.0 14.256 6.2077 100.0 15.150 5.8432 28.5 16.606 5.3342 29.7 17.856 4.9633 49.9 18.353 4.8301 20.9 19.587 4.5284 7.8 20.187 4.3952 19.5 20.955 4.2357 17.2 21.696 4.0928 15.4 23.242 3.8239 41.8 24.800 3.5871 13.5 25.237 3.5260 5.2 25.948 3.4310 17.2 27.449 3.2467 16.2 28.794 3.0979 8.1 29.956 2.9804 2.5 30.997 2.8826 5.9 32.661 2.7395 0.9 33.210 2.6955 3.2 33.801 2.6497 2.6 34.398 2.6050 1.6 35.600 2.5197 1.7 36.145 2.4830 11.9 37.107 2.4208 4.0 37.801 2.3780 1.4 38.531 2.3346 2.1

EXAMPLE 21 Crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyI-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II)

Following the general procedure of EXAMPLE 7 and making non-critical variations another sample of crystalline 17&bgr;-hydroxy-7&agr;-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, &ggr;-lactone (II) is subjected to PXRD with the following results: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) 6.545 13.4926 1.6 10.598 8.3404 27.3 11.595 7.6258 15.6 12.735 6.9456 2.9 14.296 6.1902 100 15.193 5.8268 29.5 16.649 5.3203 28.8 17.902 4.9506 41.1 18.399 4.8181 31.6 19.561 4.5344 10.4 20.153 4.4025 24 21.049 4.2171 21.4 21.708 4.0906 14.8 23.253 3.8222 38.7 24.804 3.5865 13.4 25.289 3.5189 6.8 26.006 3.4235 18.2 27.492 3.2416 15.7 28.802 3.0972 9 29.998 2.9764 2.6 30.961 2.8859 8.2 32.719 2.7348 1.5 33.293 2.6889 3.8 33.756 2.6531 2.8 36.156 2.4823 11 37.113 2.4204 6.2 37.863 2.3742 1 38.550 2.3335 2.1


Anspruch[de]
Verbindung der Formel in kristalliner Form, die ein Muster des Röntgenpulverdiffraktionsspektrums eines Zwei-Theta-Winkels (°) mit einem Bereich von etwa bis etwa 6.46 6.59 10.46 10.70 11.48 11.70 12.55 12.79 14.19 14.36 15.06 15.30 16.10 16.65 16.55 16.74 17.79 18.01 18.25 18.46 19.46 19.70 20.06 20.30 20.86 21.25 21.60 21.80 23.14 23.35 24.74 24.95 25.15 25.96 25.85 26.05 27.35 27.55 28.26 28.90 28.75 28.85 29.91 30.14 30.90 31.10 31.86 32.05 32.59 32.79 33.14 33.89 33.63 34.00 34.27 34.49 35.52 35.75 36.06 36.30 37.02 37.21 37.74 37.91 38.42 38.64 39.35 39.39
aufweist, wobei

der Zwei-Theta-Winkel in Grad gemessen ist.
Verbindung gemäß Anspruch 1, die ein mittleres Röntgenpulverdiffraktionsspektrum von etwa: Mittlerer Zwei-Theta-Winkel (°) 6.53 10.59 11.58 12.68 14.28 15.18 16.35 16.64 17.90 18.38 19.58 20.17 21.05 21.71 23.25 24.82 25.32 25.95 27.45 28.44 28.80 30.01 31.00 31.97 32.69 33.32 33.80 34.37 35.65 36.17 37.12 37.83 38.53 39.37
aufweist.
Verbindung gemäß Anspruch 1, die ein Muster eines Röntgenpulverdiffraktionsspektrums mit einem Zwei-Theta-Winkel (°) und einer relativen Intensität (%) mit Bereichen von Zwei-Theta-Winkel (°) Relative Intensität (%) Von etwa bis etwa Von etwa bis etwa 6.46 6.59 1.0 1.6 10.46 10.70 10.7 58.3 11.48 11.70 11.7 20.8 12.55 12.79 2.2 4.2 14.19 14.36 14.4 100.0 15.06 15.30 15.3 29.5 16.10 16.65 7.2 50.3 16.55 16.74 16.7 66.4 17.79 18.01 18.0 100.0 18.25 18.46 18.5 34.5 19.46 19.70 6.1 12.6 20.06 20.30 19.5 28.1 20.86 21.25 16.1 36.3 21.60 21.80 10.8 20.0 23.14 23.35 23.3 48.0 24.74 24.95 11.5 19.0 25.15 25.96 4.4 30.3 25.85 26.05 12.1 31.2 27.35 27.55 9.5 22.7 28.26 28.90 2.1 6.2 28.75 28.85 6.6 11.1 29.91 30.14 1.9 3.5 30.90 31.30 5.6 10.4 31.86 32.05 1.2 3.7 32.59 32.79 0.9 2.3 33.14 33.89 1.6 4.5 33.63 34.00 1.1 4.9 34.27 34.49 1.4 2.2 35.52 35.75 1.3 3.9 36.06 36.30 7.9 27.0 37.02 37.21 3.9 6.2 37.74 37.91 1.0 2.2 38.42 38.64 1.2 2.9 39.35 39.39 1.6 1.8
aufweist, wobei der Zwei-Theta-Winkel in Grad gemessen ist und die relative Intensität die prozentuale Intensität jedes Peaks relativ zum stärksten Peak ist.
Verbindung gemäß Anspruch 1, die ein mittleres Muster eines Röntgenpulverdiffraktionsspektrums von etwa und einer mittleren relativen Intensität von etwa: Mittlerer Zwei-Theta-Winkel (°) Mittlere relative Intensität (%) 6.53 1.3 10.59 40.9 11.58 15.9 12.68 2.9 14.28 98.2 15.18 26.1 16.35 18.7 16.64 40.3 17.90 62.9 18.38 27.7 19.58 9.4 20.17 23.8 21.05 25.1 21.71 15.6 23.25 36.4 24.82 13.5 25.32 8.4 25.95 23.1 27.45 17.0 28.44 3.8 28.80 8.5 30.01 2.5 31.00 7.9 31.97 2.5 32.69 1.7 33.32 3.4 33.80 2.7 34.37 1.7 35.65 2.5 36.1 15.3 37.12 4.8 37.83 1.6 38.53 2.3 39.37 1.7
aufweist.
Verbindung gemäß Anspruch 1, die ein Muster eines Röntgenpulverdiffraktionsspektrums von: Zwei-Theta-Winkel(°) d-Spacing (Å) relative Intensität (%) Von etwa bis etwa Von etwa bis etwa Von etwa bis etwa 6.46 6.59 13.39 13.66 1.0 1.6 10.46 10.70 8.26 8.45 10.7 58.3 11.48 11.70 7.56 7.70 11.7 20.8 12.55 12.79 6.92 7.05 2.2 4.2 14.19 14.36 6.16 6.24 14.4 100.0 15.06 15.30 5.79 5.88 15.3 29.5 16.10 16.65 5.32 5.50 7.2 50.3 16.55 16.74 5.29 5.35 16.7 66.4 17.79 18.01 4.92 4.98 18.0 100.0 18.25 18.46 4.80 4.86 18.5 34.5 19.46 19.70 4.50 4.56 6.1 12.6 20.06 20.30 4.37 4.42 19.5 28.1 20.86 21.25 4.18 4.26 16.1 36.3 21.60 21.80 4.07 4.11 10.8 20.0 23.14 23.35 3.81 3.84 23.3 48.0 24.74 24.95 3.57 3.60 11.5 19.0 25.15 25.96 3.43 3.54 4.4 30.3 25.85 26.05 3.42 3.44 12.1 31.2 27.35 27.55 3.24 3.26 9.5 22.7 28.26 28.90 3.09 3.16 2.1 6.2 28.75 28.85 3.09 3.10 6.6 11.1 29.91 30.14 2.96 2.98 1.9 3.5 30.90 31.10 2.87 2.89 5.6 10.4 31.86 32.05 2.79 2.81 1.2 3.7 32.59 32.79 2.73 2.75 0.9 2.3 33.14 33.89 2.64 2.70 1.6 4.5 33.63 34.00 2.63 2.66 1.1 4.9 34.27 34.49 2.60 2.61 1.4 2.2 35.52 35.75 2.51 2.53 1.3 3.9 36.06 36.30 2.47 2.49 7.9 27.0 37.02 37.21 2.41 2.43 3.9 6.2 37.74 37.91 2.37 2.38 1.0 2.2 38.42 38.64 2.33 2.34 1.2 2.9 39.35 39.39 2.29 2.29 1.6 1.8
aufweist, wobei der Zwei-Theta-Winkel in Grad gemessen ist, d-Spacing in Ångström gemessen ist und die relative Intensität die prozentuale Intensität jedes Peaks relativ zum stärksten Peak ist.
Verbindung gemäß Anspruch 1, die ein mittleres Muster eines Röntgenpulverdiffraktionsspektrums von etwa, ein mittleres d-Spacing von etwa und eine mittlere relative Intensität von etwa: Mittlerer Zwei-Theta-Winkel(°) Mittleres d-Spacing (Å) Mittlere Intensität (%) 6.53 13.52 1.3 10.59 8.35 40.9 11.58 7.63 15.9 12.68 6.98 2.9 14.28 6.20 98.2 15.18 5.83 26.1 16.35 5.42 18.7 16.64 5.32 40.3 17.90 4.95 62.9 18.38 4.82 27.7 19.58 4.53 9.4 20.17 4.40 23.8 21.05 4.22 25.1 21.71 4.09 15.6 23.25 3.82 36.4 24.82 3.58 13.5 25.32 3.51 8.4 25.95 3.43 23.1 27.45 3.25 17.0 28.44 3.14 3.8 28.80 3.10 8.5 30.01 2.98 2.5 31.00 2.88 7.9 31.97 2.80 2.5 32.69 2.74 1.7 33.32 2.69 3.4 33.80 2.65 2.7 34.37 2.61 1.7 35.65 2.52 2.5 36.1 2.48 15.3 37.12 2.42 4.8 37.83 2.38 1.6 38.53 2.33 2.3 39.37 2.29 1.7
aufweist.
Anspruch[en]
A compound of the formula in crystalline form having an X-ray powder diffraction pattern spectrum of Two-Theta Angle (°) with a range of From about To about 6.46 6.59 10.46 10.70 11.48 11.70 12.55 12.79 14.19 14.36 15.06 15.30 16.10 16.65 16.55 16.74 17.79 18.01 18.25 18.46 19.46 19.70 20.06 20.30 20.86 21.25 21.60 21.80 23.14 23.35 24.74 24.95 25.15 25.96 25.85 26.05 27.35 27.55 28.26 28.90 28.75 28.85 29.91 30.14 30.90 31.10 31.86 32.05 32.59 32.79 33.14 33.89 33.63 34.00 34.27 34.49 35.52 35.75 36.06 36.30 37.02 37.21 37.74 37.91 38.42 38.64 39.35 39.39
where

Two-Theta Angle is measured in degrees.
The compound according to claim 1 having an average powder X-ray diffraction spectrum of about: Two-Theta Angle (°) average 6.53 10.59 11.58 12.68 14.28 15.18 16.35 16.64 17.90 18.38 19.58 20.17 21.05 21.71 23.25 24.82 25.32 25.95 27.45 28.44 28.80 30.01 31.00 31.97 32.69 33.32 33.80 34.37 35.65 36.17 37.12 37.83 38.53 39.37
The compound according to claim 1 having an X-ray powder diffraction pattern spectrum of: Two-Theta Angle (°) and Relative Intensity (%) with ranges of Two-Theta Angle (°) Relative Intensity (%) From about To about From about To about 6.46 6.59 1.0 1.6 10.46 10.70 10.7 58.3 11.48 11.70 11.7 20.8 12.55 12.79 2.2 4.2 14.19 14.36 14.4 100.0 15.06 15.30 15.3 29.5 16.10 16.65 7.2 50.3 16.55 16.74 16.7 66.4 17.79 18.01 18.0 100.0 18.25 18.46 18.5 34.5 19.46 19.70 6.1 12.6 20.06 20.30 19.5 28.1 20.86 21.25 16.1 36.3 21.60 21.80 10.8 20.0 23.14 23.35 23.3 48.0 24.74 24.95 11.5 19.0 25.15 25.96 4.4 30.3 25.85 26.05 12.1 31.2 27.35 27.55 9.5 22.7 28.26 28.90 2.1 6.2 28.75 28.85 6.6 11.1 29.91 30.14 1.9 3.5 30.90 31.30 5.6 10.4 31.86 32.05 1.2 3.7 32.59 32.79 0.9 2.3 33.14 33.89 1.6 4.5 33.63 34.00 1.1 4.9 34.27 34.49 1.4 2.2 35.52 35.75 1.3 3.9 36.06 36.30 7.9 27.0 37.02 37.21 3.9 6.2 37.74 37.91 1.0 2.2 38.42 38.64 1.2 2.9 39.35 39.39 1.6 1.8
where Two-Theta Angle is measured in degrees and Relative Intensity is the intensity percentage of each peak relative to the strongest peak.
The compound according to claim 1 having an average X-ray powder diffraction pattern spectrum of about and an average Relative Intensity of about: Two-Theta Angle (°) average Relative Intensity (%) average 6.53 1.3 10.59 40.9 11.58 15.9 12.68 2.9 14.28 98.2 15.18 26.1 16.35 18.7 16.64 40.3 17.90 62.9 18.38 27.7 19.58 9.4 20.17 23.8 21.05 25.1 21.71 15.6 23.25 36.4 24.82 13.5 25.32 8.4 25.95 23.1 27.45 17.0 28.44 3.8 28.80 8.5 30.01 2.5 31.00 7.9 31.97 2.5 32.69 1.7 33.32 3.4 33.80 2.7 34.37 1.7 35.65 2.5 36.1 15.3 37.12 4.8 37.83 1.6 38.53 2.3 39.37 1.7
The compound according to claim 1 having an X-ray powder diffraction pattern spectrum of: Two-Theta Angle (°) d-spacing ( ) Relative Intensity (%) From About To About From About To About From About To About 6.46 6.59 13.39 13.66 1.0 1.6 10.46 10.70 8.26 8.45 10.7 58.3 11.48 11.70 7.56 7.70 11.7 20.8 12.55 12.79 6.92 7.05 2.2 4.2 14.19 14.36 6.16 6.24 14.4 100.0 15.06 15.30 5.79 5.88 15.3 29.5 16.10 16.65 5.32 5.50 7.2 50.3 16.55 16.74 5.29 5.35 16.7 66.4 17.79 18.01 4.92 4.98 18.0 100.0 18.25 18.46 4.80 4.86 18.5 34.5 19.46 19.70 4.50 4.56 6.1 12.6 20.06 20.30 4.37 4.42 19.5 28.1 20.86 21.25 4.18 4.26 16.1 36.3 21.60 21.80 4.07 4.11 10.8 20.0 23.14 23.35 3.81 3.84 23.3 48.0 24.74 24.95 3.57 3.60 11.5 19.0 25.15 25.96 3.43 3.54 4.4 30.3 25.85 26.05 3.42 3.44 12.1 31.2 27.35 27.55 3.24 3.26 9.5 22.7 28.26 28.90 3.09 3.16 2.1 6.2 28.75 28.85 3.09 3.10 6.6 11.1 29.91 30.14 2.96 2.98 1.9 3.5 30.90 31.10 2.87 2.89 5.6 10.4 31.86 32.05 2.79 2.81 1.2 3.7 32.59 32.79 2.73 2.75 0.9 2.3 33.14 33.89 2.64 2.70 1.6 4.5 33.63 34.00 2.63 2.66 1.1 4.9 34.27 34.49 2.60 2.61 1.4 2.2 35.52 35.75 2.51 2.53 1.3 3.9 36.06 36.30 2.47 2.49 7.9 27.0 37.02 37.21 2.41 2.43 3.9 6.2 37.74 37.91 2.37 2.38 1.0 2.2 38.42 38.64 2.33 2.34 1.2 2.9 39.35 39.39 2.29 2.29 1.6 1.8
where Two-Theta Angle is measured in degrees, d-Spacing is measured in angstroms, and Relative Intensity is the intensity percentage of each peak relative to the strongest peak.
The compound according to claim 1 having a average powder X-ray diffraction pattern spectrum of about, an average d-Spacing of about and an average Relative Intensity of about: Two-Theta Angle d-spacing Relative Intensity (°) average ( ) average (%) average 6.53 13.52 1.3 10.59 8.35 40.9 11.58 7.63 15.9 12.68 6.98 2.9 14.28 6.20 98.2 15.18 5.83 26.1 16.35 5.42 18.7 16.64 5.32 40.3 17.90 4.95 62.9 18.38 4.82 27.7 19.58 4.53 9.4 20.17 4.40 23.8 21.05 4.22 25.1 21.71 4.09 15.6 23.25 3.82 36.4 24.82 3.58 13.5 25.32 3.51 8.4 25.95 3.43 23.1 27.45 3.25 17.0 28.44 3.14 3.8 28.80 3.10 8.5 30.01 2.98 2.5 31.00 2.88 7.9 31.97 2.80 2.5 32.69 2.74 1.7 33.32 2.69 3.4 33.80 2.65 2.7 34.37 2.61 1.7 35.65 2.52 2.5 36.1 2.48 15.3 37.12 2.42 4.8 37.83 2.38 1.6 38.53 2.33 2.3 39.37 2.29 1.7
Anspruch[fr]
Composé de la formule : sous forme cristalline présentant un spectre d'aspect de diffraction aux rayons X pour poudre d'un angle deux thêta (°) avec une plage D'environ A environ 6,46 6,59 10,46 10,70 11,48 11,70 12,55 12,79 14,19 14,36 15,06 15,30 16,10 16,65 16,55 16,74 17,79 18,01 18,25 18,46 19,46 19,70 20,06 20,30 20,86 21,25 21,60 21,80 23,14 23,35 24,74 24,95 25,15 25,96 25,85 26,05 27,35 27,55 28,26 28,90 28,75 28,85 29,91 30,14 30,90 31,10 31,86 32,05 32,59 32,79 33,14 33,89 33,63 34,00 34,27 34,49 35,52 35,75 36,06 36,30 37,02 37,21 37,74 37,91 38,42 38,64 39,35 39,39
où l'angle deux thêta est mesuré en degrés.
Composé selon la revendication 1, présentant un spectre de diffraction aux rayons X pour poudre moyen d'environ : Angle deux thêta (°) moyen 6,53 10,59 11,58 12,68 14,28 15,18 16,35 16,64 17,90 18,38 19,58 20,17 21,05 21,71 23,25 24,82 25,32 25,95 27,45 28,44 28,80 30,01 31,00 31,97 32,69 33,32 33,80 34,37 35,65 36,17 37,12 37,83 38,53 39,37
Composé selon la revendication 1, présentant un spectre d'aspect de diffraction aux rayons X pour poudre : d'un angle deux thêta (°) et d'une intensité relative (%) avec des plages Angle deux thêta (°) Intensité relative (%) D'environ A environ D'environ A environ 6,46 6,59 1,0 1,6 10,46 10,70 10,7 58,3 11,48 11,70 11,7 20,8 12,55 12,79 2,2 4,2 14,19 14,36 14,4 100,0 15,06 15,30 15,3 29,5 16,10 16,65 7,2 50,3 16,55 16,74 16,7 66,4 17,79 18,01 18,0 100,0 18,25 18,46 18,5 34,5 19,46 19,70 6,1 12,6 20,06 20,30 19,5 28,1 20,86 21,25 16,1 36,3 21,60 21,80 10,8 20,0 23,14 23,35 23,3 48,0 24,74 24,95 11,5 19,0 25,15 25,96 4,4 30,3 25,85 26,05 12,1 31,2 27,35 27,55 9,5 22,7 28,26 28,90 2,1 6,2 28,75 28,85 6,6 11,1 29,91 30,14 1,9 3,5 30,90 31,30 5,6 10,4 31,86 32,05 1,2 3,7 32,59 32,79 0,9 2,3 33,14 33,89 1,6 4,5 33,63 34,00 1,1 4,9 34,27 34,49 1,4 2,2 35,52 35,75 1,3 3,9 36,06 36,30 7,9 27,0 37,02 37,21 3,9 6,2 37,74 37,91 1,0 2,2 38,42 38,64 1,2 2,9 39,35 39,39 1,6 1,8
l'angle deux thêta est mesuré en degrés et l'intensité relative est le pourcentage d'intensité de chaque pic par rapport au pic le plus fort.
Composé selon la revendication 1, présentant un spectre d'aspect de diffraction aux rayons X pour poudre moyen d'environ et une intensité relative moyenne d'environ : Angle deux thêta (°) Intensité relative (%) moyen moyenne 6,53 1,3 10,59 40,9 11,58 15,9 12,68 2,9 14,28 98,2 15,18 26,1 16,35 18,7 16,64 40,3 17,90 62,9 18,38 27,7 19,58 9,4 20,17 23,8 21,05 25,1 21,71 15,6 23,25 36,4 24,82 13,5 25,32 8,4 25,95 23,1 27,45 17,0 28,44 3,8 28,80 8,5 30,01 2,5 31,00 7,9 31,97 2,5 32,69 1,7 33,32 3,4 33,80 2,7 34,37 1,7 35,65 2,5 36,1 15,3 37,12 4,8 37,83 1,6 38,53 2,3 39,37 1,7
Composé selon la revendication 1, présentant un spectre d'aspect de diffraction aux rayons X pour poudre de : Angle deux thêta (°) Distance d (Å) Intensité relative (%) D'environ A environ D'environ A environ D'environ A environ 6,46 6,59 13,39 13,66 1,0 1,6 10,46 10,70 8,26 8,45 10,7 58,3 11,48 11,70 7,56 7,70 11,7 20,8 12,55 12,79 6,92 7,05 2,2 4,2 14,19 14,36 6,16 6,24 14,4 100,0 15,06 15,30 5,79 5,88 15,3 29,5 16,10 16,65 5,32 5,50 7,2 50,3 16,55 16,74 5,29 5,35 16,7 66,4 17,79 18,01 4,92 4,98 18,0 100,0 18,25 18,46 4,80 4,86 18,5 34,5 19,46 19,70 4,50 4,56 6,1 12,6 20,06 20,30 4,37 4,42 19,5 28,1 20,86 21,25 4,18 4,26 16,1 36,3 21,60 21,80 4,07 4,11 10,8 20,0 23,14 23,35 3,81 3,84 23,3 48,0 24,74 24,95 3,57 3,60 11,5 19,0 25,15 25,96 3,43 3,54 4,4 30,3 25,85 26,05 3,42 3,44 12,1 31,2 27,35 27,55 3,24 3,26 9,5 22,7 28,26 28,90 3,09 3,16 2,1 6,2 28,75 28,85 3,09 3,10 6,6 11,1 29,91 30,14 2,96 2,98 1,9 3,5 30,90 31,10 2,87 2,89 5,6 10,4 31,86 32,05 2,79 2,81 1,2 3,7 32,59 32,79 2,73 2,75 0,9 2,3 33,14 33,89 2,64 2,70 1,6 4,5 33,63 34,00 2,63 2,66 1,1 4,9 34,27 34,49 2,60 2,61 1,4 2,2 35,52 35,75 2,51 2,53 1,3 3,9 36,06 36,30 2,47 2,49 7,9 27,0 37,02 37,21 2,41 2,43 3,9 6,2 37,74 37,91 2,37 2,38 1,0 2,2 38,42 38,64 2,33 2,34 1,2 2,9 39,35 39,39 2,29 2,29 1,6 1,8
l'angle deux thêta (°) est mesuré en degrés, la distance d est mesurée en angströms, et l'intensité relative est le pourcentage d'intensité de chaque pic par rapport au pic le plus fort.
Composé selon la revendication 1, présentant un spectre d'aspect de diffraction aux rayons X pour poudre moyen d'environ, une distance d moyenne d'environ et une intensité relative moyenne d'environ : Angle deux thêta (°) moyen Distance d (Å) moyenne Intensité relative (%) moyenne 6,53 13,52 1,3 10,59 8,35 40,9 11,58 7,63 15,9 12,68 6,98 2,9 14,28 6,20 98,2 15,18 5,83 26,1 16,35 5,42 18,7 16,64 5,32 40,3 17,90 4,95 62,9 18,38 4,82 27,7 19,58 4,53 9,4 20,17 4,40 23,8 21,05 4,22 25,1 21,71 4,09 15,6 23,25 3,82 36,4 24,82 3,58 13,5 25,32 3,51 8,4 25,95 3,43 23,1 27,45 3,25 17,0 28,44 3,14 3,8 28,80 3,10 8,5 30,01 2,98 2,5 31,00 2,88 7,9 31,97 2,80 2,5 32,69 2,74 1,7 33,32 2,69 3,4 33,80 2,65 2,7 34,37 2,61 1,7 35,65 2,52 2,5 36,1 2,48 15,3 37,12 2,42 4,8 37,83 2,38 1,6 38,53 2,33 2,3 39,37 2,29 1,7






IPC
A Täglicher Lebensbedarf
B Arbeitsverfahren; Transportieren
C Chemie; Hüttenwesen
D Textilien; Papier
E Bauwesen; Erdbohren; Bergbau
F Maschinenbau; Beleuchtung; Heizung; Waffen; Sprengen
G Physik
H Elektrotechnik

Anmelder
Datum

Patentrecherche

Patent Zeichnungen (PDF)

Copyright © 2008 Patent-De Alle Rechte vorbehalten. eMail: info@patent-de.com